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Abstract
The aim of this chapter is to assess the effectiveness of non-pharmacologic 
therapies like progressive muscle relaxation therapy (PMRT) as an adjunctive 
therapy for reducing level of depression for multiple sclerosis (MS) patients. One 
of the most common mood disorders is major depressive disorder (MDD) that 
MS patients experience it during their lives. MDD can exacerbate the symptoms 
of the MS disease. Non-pharmacologic therapies were held for the MS patients, 
twelve sessions of PMRT using Bernstein and Borkovec’s method in spring 2010. 
According to the results, PMRT is effective in reducing depression. This therapy 
enables patients to reach relaxation quickly and thus can cope with depression 
reactions effectively.
Keywords: non-pharmacologic therapies, multiple sclerosis, depression,  
progressive muscle relaxation therapy
1. Introduction
These days the goal of all current and emerging therapeutic strategies for 
multiple sclerosis (MS) patients is to return them to a normal life despite of the 
disease [1].
Currently there is not any definitive treatment for MS disease and medications 
only reduce relapse rate, prolong remission, limit the onset of new MS lesions, and 
postpone the development of long-term disability [2].
Pharmacologic therapies (modafinil, dalfampridine, baclofen, diazepam, gaba-
pentin, opioids) are used for symptomatic treatment of disability and symptoms, 
but these do not improve disease outcome [2].
The cause and cure is unknown; appearing, removing and even relapsing of 
symptoms occurs without any signs warning [3] and the onset of the disease may be 
acute or gradual [1]. Strong evidence for irreversible neurological disability in MS 
patients indicates that MS disease is an autoimmune disease against central nervous 
system myelin or neuron degeneration [4].
MS disease may prevent from some patients activities such as; employment, 
relationships (social, familial), goals and long term plans and activities of daily 
living [3]. Therefore these disabilities will challenge persons with MS disease, when 
they are attempting to pursue an active and compatible lifestyle [5].
Variable courses in MS disease are common. Within two to three decades, this 
disease changes from recoverable to unrecoverable neurological disorder and stable 
disability [6].
One million people in the world suffer from MS disease that has been reported 
1.8 times more in females than males. MS is co morbid with psychiatric disorders 
and has a profound effect on the personal lives of individuals [7, 8].
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The psychosocial factors are closely associated with MS onset and may play 
important roles in the development of the disease [9].
MS disease usually indicates disparate disease periods and interaction between 
medical and psychological variables in MS disease is complex [7].
People with multiple sclerosis (MS) often report depression, poor sleep, fatigue, 
sleepiness and cognitive dysfunction. Interrelationships between symptoms are 
poorly understood [10].
For example findings suggest that treatment for depression is associated with 
reductions in the severity of fatigue symptoms [11] and many patients with mul-
tiple sclerosis (MS) report that stress can exacerbate disease [12].
Cognitive impairment is common in this disease [13]. Prevalence of cognitive 
impairment is about 30.5% and affects attention, concentration, performance, 
processing speed and visual perception [14].
These data point out the importance of orienting therapeutic interventions. For 
managing the symptoms of MS disease and improving or maintaining function and 
preserving the patient’s quality of life are recommended careful clinical monitoring 
and pharmacologic and non-pharmacologic therapies [15].
Non-pharmacologic therapeutic strategies include psychotherapy, cognitive 
behavioral therapy, strengthen of coping, progressive muscle relaxation therapy 
(PMRT), etc. [16].
Non-pharmacologic therapies are used widely by MS patients and progressive 
muscle relaxation therapy (PMRT) is a form of complementary therapies [17].
For the first time Jacobson in 1934 recognized that the mind and selected 
muscles (16 muscle groups) work together in a united way. It means body can be 
relaxed with mental relaxation and mind can be relaxed with progressive muscle 
relaxation therapy (PMRT) [18].
This procedure was suited by Wolpe (1948) for systematic desensitization therapy 
and by Bernstein and Borkovec for stress management in cognitive-behavioral 
therapy in 1973. The Bernstein and Borkovec forms are brief and adapted that these 
are used generally (7 or 4 muscles groups) [18, 19].
In fact, relaxation therapy is several methods to show patients how they can 
achieve relaxation. Most programs include training special breathing and progressive 
muscle relaxation (tension-release cycles) to reduce physical and mental tension [20].
The relaxation response is a physiological state and incompatible response 
against stress response [21] and has a significant psychological impact on specific 
aspects of our personality and changing unwanted habits and attitudes [22].
Muscle tension is associated with stress and anxiety, which are related with 
depression strongly [20]. Depression had a negative impact on all quality of life 
domains and anxiety impact on mental domains [23].
It seems that unpredictable courses of disease activity influence in many differ-
ent fields of their life. Unpredictable periods can make severe feelings of helpless-
ness and depression in patients with MS [7], also the hopelessness hypothesis states 
that unpredictable and negative events of life patients leads to depression [24].
Depression is the predominant psychological disturbance with lifetime prevalence 
around 50% and annual prevalence of 20%. With diagnosis of MS, anxiety increases 
and depression is commoner during relapses also increases the rate of suicidal ide-
ation and treating depression improves adherence to disease-modifying drugs [25].
MS patients often hide symptoms of depression and they complain from other 
symptoms [26]. Therefore treatment plans for depression among MS patients 
should be treated with individual and integrated approach [25].
According to the American Psychological Association (2018), people with 
depression may experience a lack of interest and pleasure in daily activities, 
inability to concentrate, feelings of worthlessness or excessive guilt and recurrent 
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thoughts of death or suicide (non-somatic symptoms), significant weight loss or 
gain, insomnia or excessive sleeping, lack of energy (somatic symptoms).
Significant results show that PMRT, helpfulness for human suffering from 
depression in groups with brain health (different patients, like: multiple somato-
form syndrome, cancer disease, pulmonary disease, cardiac disease, muscular pain, 
tinnitus disease and night eating syndrome) and brain lesion (MS patients).
Treatment by PMRT for depression is better than no-treatment or placebo treat-
ment or other behavioral methods treatment. The comparison between the first 
intervention and the follow up showed that the effect of the treatment remained 
(sometimes more) [27–39].
According to recent researches, it was assumed that PMRT may reduce the level 
of major depressive disorder in female MS patients in Shiraz Multiple Sclerosis Aid 
Society (SH.M.S.A.S).
2. Methods and materials
This study was an applied-experimental research with randomized controlled 
trial design plus pre and posttests.
Study included the independent variable (progressive muscle relaxation therapy 
PMRT) and dependent variable (depression).
This study compared two groups; experimental and control.
The first group received (PMRT) and the second group did not receive any treat-
ment for depression.
In spring 2010, from 2800 MS patients in SH.M.S.A.S 30 female volunteers 
participated in this study.
They answered the questionnaire before the intervention (Beck Depression 
Inventory BDI-II).
Criteria of MS and major depressive disorder (MDD) disease from minimal to 
severe were confirmed by the SHMSAS and BDI-II.
After the pretest, cases were matched in terms such as: degree of depression age, 
marital status, education and income then randomly divided in two groups.
The experimental group received standard care for MS disease plus 60 min of 
psychological intervention (PMRT) for each session (twice a week for six weeks) by 
M.A Clinical Psychology in Society of MS.
The control group received only standard care for MS disease.
Until the end of the treatment, drop out did not occur in the number of patients 
and two groups cooperated again in the posttest (answered the questionnaire for the 
second time).
2.1 Rights and criteria
Ethical considerations and rights were applied for this research (respect to basic 
rights of patients such as; privacy, cultural and social values, freedom of choice and 
honesty about characteristics of therapy and therapist’s competence).
Selection criteria:
1. Willing to attend in therapy meeting.
2. Having physical ability and minimal level of literacy was sufficient.
3. Accepting the philosophy of doing daily assignments and filling out weekly 
notes.
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2.2 The content of therapy sessions
The best way for muscle relaxation is for muscles to be contracted as much 
as possible, and then be relaxed suddenly (tension-release sequence). The released 
force from the treatment increases the excitability threshold. The released force 
is a big step toward deeper relaxation and patients can understand the feeling of 
tension and relaxation of muscles (comparative judgment). Relaxation therapy was 
divided to two parts:
1. The first six sessions: special breathing plus contraction and relaxation of 
muscles, with gradual reduction of the number of muscles involved.
2. The second six sessions: special breathing plus contraction and relaxation of 
mind [21].
2.3 Tools
In this intervention for therapy meetings, Progressive Muscle Relaxation, was 
used by method of Bernstein and Borkovec, 1973 [18], also the Beck Depression 
Questionnaire (Beck, Epstein, Brown and Steer, 1988) was used, with the reliability 
(0.91) and validity (0.87) of the Iranian valid [40].
The BDI-II was expanded based on criteria of diagnostic and statistical 
manual of mental disorders, fourth edition (DSM-IV) for diagnosing depressive 
disorders [41].
The BDI-II is a brief scale that it is suitable for researchers as a screening tool. It 
is a subjective paper and pencil questionnaire with ordinal scale. In addition cut-off 
points (0–13), (14–19), (20–28) and (29–63) show minimal, mild, moderate and 
severe depression [41].
2.4 Iranian validation
Based on Iranian Validation, validity was certified by positive correlation, 
between Beck Depression Inventory (BDI-II) and Brief Symptom Inventory (BSI), 
coefficient of Pearson was 0.87, and factor analysis showed physical factor, cogni-
tive factor and affective factor.
And reliability was certified by method of internal consistency, Cronbach’s alpha 
coefficient was 0.91 [40].
2.5 Analysis method of data
To remove covariate variable was applied Analysis of Covariance and to remove 
difference between two groups was applied Levine Test.
In this intervention, the variables were Progressive Muscle Relaxation Therapy 
as independent and Depression as dependent variable after that analysis of Variance 
was applied with technique of Repeated Measures.
3. Results
Thirty MS patients attended in this intervention that they were separated 
randomly in two groups (experimental and control). Tables 1 and 2 was designed 
for context variables and descriptive statistics of depression.
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Table 1, shows half of patients in this intervention were sick more than 5 years 
and they had tolerated symptoms from mild to severe and they were in the third 
decade of their life and in status of marital single patients were more than others. 
Also in education degree most of them had a bachelor’s degree.
All patients had depression and some of them had severe depression that in 
experimental group the mean value indicates mild depression (the results are rav-
eled in Table 2).
The intervention hypothesis explains that PMRT may reduce the level of depres-
sive disorder. This assumption was checked by Tables 3–5.
Table 3, was designed to measure the equality of variances between groups.
The results indicate that there was no significant difference in the variance of 
groups.
The purpose of Covariance Analysis in Table 4 was to eliminate of the covariate 
variable from the dependent variable and to estimate the central indexes.
After intervention, with notice to the significance level and after omitting the 
impact of pretest on posttest, finding revealed the mean and standard deviation 
has increased (reduce depression). A significant reduction in depression variable 
occurred in seven levels.
In Table 5, Analysis of Variance with Repeated Measures method reviewed the 
impact of intervention on depression.
Table 5 showed that the difference between pretest and posttest was significant 
(p = 0.0001) and this difference was 49% reduction in depression levels, it means 
that this reduction has occurred because of the relaxation therapy and statistical 
power was 99%.
Experimental group Control group
Frequency Percentage Frequency Percentage
Sick precedent Less than 2 years 4 0.26 4 0.26
2–5 years 2 0.13 3 0.20
5–10 years 7 0.46 8 0.53
More than 
10 years
2 0.13 0 0.00
Age Second decade 5 0.33 4 0.26
Third decade 5 0.33 6 0.40
Fourth decade 4 0.26 3 0.20
Fifth decade 1 0.60 2 0.13
Marital status Single 7 0.46 5 0.33
Married 5 0.33 6 0.40
Divorced 2 0.13 2 0.13
Widow 1 0.60 2 0.13
Education 
degree
High school 3 0.20 4 0.26
Diploma 4 0.26 5 0.33
Bachelor 8 0.53 6 0.40
Master 0 0.00 0 0.00
Table 1. 
Context variable in experimental and control groups.
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4. Discussion
MS patients spent a lot of time to control emotional disorders, like depression. 
Levels of depression were studied by researchers and the results showed high levels 
of this variable and the effects of depression on MS disease exacerbation [42–59].
For example:
The possibility that the health status of negative mental can change period of 
MS disease since Charcot (1879, he was the first proposer), has been discussed, 
that shows grief and worry might influence on onset and exacerbation of disease 
symptoms [3].
F First-degree of freedom Second-degree of freedom Significant level
Depression 0.463 1 28 0.502
Table 3. 
Levine test results (about equal variances in the two groups).
Control Experimental Total
After Before After Before After Before
Mean 15.93 15.86 8.40 16.20 12.16 16.03
Median 13 13 5 16 10 14
Mode 10 11 5 11 5 11
Sum 239 238 126 243 365 481
Std. deviation 9.72 9.76 9.43 9.50 10.16 9.46
Variance 94.49 95.26 88.9 90.31 103.24 89.62
Range 31 31 40 36 40 37
Maximum 34 34 40 40 40 40
Table 2. 
Descriptive statistics of depression variable.
Experimental group Average Standard 
deviation
Number Average 
difference
Meaningful 
level
Before intervention 16.08 1.03 15 7.83 0.000
After intervention 8.24 1.03 15 −7.83 0.000
Table 4. 
The estimate of average depression variable.
Source of changes Sig Effect Statistical power
Effects Depression 0.0001 0.49 99
Interaction depression and group 0.0001 0.55 99
Error
Table 5. 
Results of variance analysis with repeated measures method.
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Negative emotions (like depression) in the MS patients correlated with their 
family troubles and social isolation [9].
Non-somatic symptoms of depression can predict cognitive performance [14] 
and on the other hand somatic and non-somatic symptoms of depression predict 
exacerbation of MS disease [60].
Depression is an important predictor parameter on psychological balance of MS 
patients [61] and studies have confirmed that there are the relationships between 
structural brain lesions with depression in MS patients [24] and may be lesion site has 
two function: increases in depression and sleep disturbance (fatigue symptoms) [62].
Previous studies have indicated that depression is prevalent in MS patients and 
affects treatment adherence and associates with the neurologic damage that results 
from multiple sclerosis [42–59].
This study was designed to purpose that with identifying and treating the first 
symptoms of depression, patients can increase the performance of themselves in 
the society.
This study was designed to assess hypothesis derived from the Gate Theory this 
theory states that psychological factors influence on physical factors of pain [physi-
cal pain and psychological pain]. It means, the same way that stress and discomfort 
can exacerbate pain, relief and relaxation can also reduce pain [63] and depression 
is an overwhelming psychological pain [64], therefore this randomized controlled 
study during twelve sessions was carried out to determine the effects of treatment 
on experimental group. The results showed that there was a significant relationship 
between treatment and depression. Table 4 shows mild depression in experimental 
group and after intervention average of depression reduction was seven levels; 
operationally it define that patients in experimental group indicated state of depres-
sion like normal people.
Analysis of Variance showed that these changes (it was 49%) in the group, were 
as a result of progressive muscle relaxation therapy.
Table 2 shows severe depression in some cases before and after treatment. They 
often hide symptoms of depression or cannot recognize between symptoms of 
depression and MS disease. Also previous treatments (like pharmacologic therapy) 
for severe depression were continued. These cases took less advantage from this 
treatment.
Measurement of depression in patients with MS is complicated because some of 
the symptoms are identical between depression and MS disease (excessive fatigue, 
cognitive difficulties, psychomotor retardation, mood changes, sleep changes and 
emotional changes) [65].
Findings of this study showed that the level of depression (first symptoms of 
depression), even in the short-term treatment has reduced, which were considered 
6 weeks (as a safe, inexpensive and effective intervention) and demonstrated the 
effectiveness of PMRT in reducing depression as non-pharmacologic treatment, 
when treatment was used systematically.
Findings of this short-term treatment were consistent with the research of 
Jorm and Morgan [20]. They confirmed that PMRT as psychological intervention 
for depression patients are more acceptable than other interventions (relaxation 
imagery, autogenic training) and finding of Annette and Jens’s study [66] demon-
strated both cognitive behavioral therapy (CBT) and PMRT appear to be effective 
treatments for depression in the normal human brain.
Based on the results of Sutherland and Andersen [3] and Artemiadis and 
Vervainioti [39] and Molina and Pérez in Spain [67] and Ghafari and Ahmadi in 
Iran [68], potentially, it could be stated that PMRT may provide benefits in differ-
ent dimensions of the disease (vitality, fatigue, depression) in the brain affected 
with MS.
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However in psychological interventions, therapist training is essential. In fact, 
relaxation technique is an acceptable psychological intervention, which this method 
requires less skill and training than other techniques.
Finally, rationale and supporting evidence, and techniques used in Progressive 
Muscle Relaxation Therapy was summarized in this article for intuitive understand-
ing of future researchers about influences of PMRT.
4.1 Suggestions
PMRT is effective treatment for depression in MS patients, although more stud-
ies should be done for investigating the relaxation therapy as a first-line treatment 
in a stepped care approach to managing depression in MS patients. Therefore, to 
obtain more accurate results, the following recommendations are given:
1. It is suggested that in future studies, should be used more objective clinical and 
laboratory studies.
2. More control of confounding variables can reduce the limitations of the study 
(such as: sex, social and cultural status and disease progression).
3. Quantity of therapy will be better by using tapes, movies or booklets and long-
term treatment.
4. Finally, it is recommended screening programs for depression in MS disease 
for facilitating access to services for all MS patients.
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